2024-03-15 19:25:03 ET
DiaSorin S.p.A. (DSRLF)
Q4 2023 Earnings Conference Call
March 15, 2024 10:00 AM ET
Company Participants
Carlo Rosa - Chief Executive Officer
Piergiorgio Pedron - Chief Financial Officer
Conference Call Participants
Aisyah Noor - Morgan Stanley
Maja Pataki - Kepler Cheuvreux
Hugo Salaun - BNP Paribas Exane
Shubhangi Gupta - HSBC
Odysseas Manesiotis - Berenberg
Presentation
Operator
Good afternoon, this is the Chorus Call conference operator. Welcome, and thank you for joining the DiaSorin Full-Year 2023 Results Conference Call. As a reminder, all participants are in listen-only mode. After the presentation, there will be an opportunity to ask questions. [Operator Instructions]
At this time, I would like to turn the conference over to Mr. Carlo Rosa, CEO of DiaSorin. Please go ahead, sir.
Carlo Rosa
Thank you, operator. Good morning, good afternoon to everybody. Welcome to the 2023 full-year results. As usual, I'm going to make some initial strategic remarks, and then the Chief Financial Officer, Piergiorgio is going to take you through the numbers.
As a general comment, let me say that 2023 was a very, very busy year. It was the second year after the acquisition of Luminex, and has been -- we completed our integration plan with the company. And we -- I would like to say that by December of last year, integration is done, the strategic role of Luminex has been defined. The senior leadership team has been set in place, the branding of Luminex has been defined. And today, Luminex is a brand that we are using just for our LTG products, whereas all IVD products, molecular and immuno, goes under DiaSorin.
From an operation point of view, we have invested heavily in our quality system, and I think it's noteworthy that we have closed the warning letter with the FDA, and we have completed our investment in manufacturing in the Chicago plant, and we are on the way to complete also the California plant where the next manufacturing will happen....
Read the full article on Seeking Alpha
For further details see:
DiaSorin S.p.A. (DSRLF) Q4 2023 Earnings Call Transcript